These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28880550)

  • 1. A Polymer Therapeutic Having Universal Heparin Reversal Activity: Molecular Design and Functional Mechanism.
    Kalathottukaren MT; Abbina S; Yu K; Shenoi RA; Creagh AL; Haynes C; Kizhakkedathu JN
    Biomacromolecules; 2017 Oct; 18(10):3343-3358. PubMed ID: 28880550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.
    Kalathottukaren MT; Abraham L; Kapopara PR; Lai BF; Shenoi RA; Rosell FI; Conway EM; Pryzdial EL; Morrissey JH; Haynes CA; Kizhakkedathu JN
    Blood; 2017 Mar; 129(10):1368-1379. PubMed ID: 28034889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants.
    Shenoi RA; Kalathottukaren MT; Travers RJ; Lai BF; Creagh AL; Lange D; Yu K; Weinhart M; Chew BH; Du C; Brooks DE; Carter CJ; Morrissey JH; Haynes CA; Kizhakkedathu JN
    Sci Transl Med; 2014 Oct; 6(260):260ra150. PubMed ID: 25355700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors.
    Kalathottukaren MT; Creagh AL; Abbina S; Lu G; Karbarz MJ; Pandey A; Conley PB; Kizhakkedathu JN; Haynes C
    Blood Adv; 2018 Aug; 2(16):2104-2114. PubMed ID: 30135185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion-Sequestration Mechanism.
    Lin F; Yu SB; Liu YY; Liu CZ; Lu S; Cao J; Qi QY; Zhou W; Li X; Liu Y; Tian J; Li ZT
    Adv Mater; 2022 Jun; 34(23):e2200549. PubMed ID: 35499202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheological and clot microstructure evaluation of heparin neutralization by UHRA and protamine.
    Yeh HH; Yu K; Vappala S; Kalathottukaren MT; Abbina S; Luo HD; Grecov D; Kizhakkedathu JN
    J Mech Behav Biomed Mater; 2021 Dec; 124():104851. PubMed ID: 34600430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The toxicology of heparin reversal with protamine: past, present and future.
    Sokolowska E; Kalaska B; Miklosz J; Mogielnicki A
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):897-909. PubMed ID: 27223896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.
    Kalathottukaren MT; Haynes CA; Kizhakkedathu JN
    Drug Deliv Transl Res; 2018 Aug; 8(4):928-944. PubMed ID: 28741113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Steric Shield on Biocompatibility and Antithrombotic Activity of Dendritic Polyphosphate Inhibitor.
    Abbina S; La CC; Vappala S; Kalathottukaren MT; Abbasi U; Gill A; Smith SA; Haynes CA; Morrissey JH; Kizhakkedathu JN
    Mol Pharm; 2022 Jun; 19(6):1853-1865. PubMed ID: 35500201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats.
    Kalaska B; Miklosz J; Kamiński K; Swieton J; Jakimczuk A; Yusa SI; Pawlak D; Nowakowska M; Szczubiałka K; Mogielnicki A
    J Pharmacol Exp Ther; 2020 Apr; 373(1):51-61. PubMed ID: 31937564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant activity and pleiotropic effects of heparin.
    Bal Dit Sollier C; Dillinger JG; Drouet L
    J Med Vasc; 2020 May; 45(3):147-157. PubMed ID: 32402428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote.
    La CC; Smith SA; Kalathottukaren MT; Haynes CA; Morrissey JH; Kizhakkedathu JN
    Adv Healthc Mater; 2024 Mar; ():e2400108. PubMed ID: 38537246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical and pharmacological aspects of neutralization of heparins from different animal sources by protamine.
    Glauser BF; Santos GRC; Silva JD; Tovar AMF; Pereira MS; Vilanova E; Mourão PAS
    J Thromb Haemost; 2018 Sep; 16(9):1789-1799. PubMed ID: 29968421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caltrop-like Small-Molecule Antidotes That Neutralize Unfractionated Heparin and Low-Molecular-Weight Heparin In Vivo.
    Zong Y; Lei Z; Yu SB; Zhang LY; Wu Y; Feng K; Qi QY; Liu Y; Zhu Y; Guo P; Zhou W; Zhang DW; Li ZT
    J Med Chem; 2024 Mar; 67(5):3860-3873. PubMed ID: 38407934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porous dynamic covalent polymers as promising reversal agents for heparin anticoagulants.
    Zong Y; Xu YY; Wu Y; Liu Y; Li Q; Lin F; Yu SB; Wang H; Zhou W; Sun XW; Zhang DW; Li ZT
    J Mater Chem B; 2022 May; 10(17):3268-3276. PubMed ID: 35357392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chitosan derivatives as novel potential heparin reversal agents.
    Kamiński K; Szczubiałka K; Zazakowny K; Lach R; Nowakowska M
    J Med Chem; 2010 May; 53(10):4141-7. PubMed ID: 20423087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo safety studies indicate that R15, a synthetic polyarginine peptide, could safely reverse the effects of unfractionated heparin.
    Li T; Meng Z; Zhu X; Gan H; Gu R; Wu Z; Liu T; Han P; Gao J; Han S; Dou G
    FEBS Open Bio; 2021 Sep; 11(9):2468-2489. PubMed ID: 34184429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
    Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.